Abstract:Multiple sclerosis (MS) is a debilitating autoimmune disease that impacts millions of patients worldwide, disproportionately impacting women (4:1), and often presenting at highly productive stages of life. This disease affects the spinal cord and brain and is characterized by severe neuroinflammation, demyelination, and subsequent neuronal damage, resulting in symptoms like loss of mobility. While untargeted and pan-immunosuppressive therapies have proven to be disease-modifying and manage (or prolong the time between) symptoms in many patients, a significant fraction are unable to achieve remission. Recent work has suggested that targeted neuroinflammation mitigation through selective inflammasome inhibition can offer relief to patients while preserving key components of immune function. Here, we show a screening of potential therapeutic targets using inflammasome-inhibiting Nanoligomers (NF-κB1, TNFR1, TNF-α, IL-6) that meet or far-exceed commercially available small-molecule counterparts like ruxolitinib, MCC950, and deucravacitinib. Using the human brain organoid model, top Nanoligomer combinations (NF-κB1 + TNFR1: NI111, and NF-κB1 + NLRP3: NI112) were shown to significantly reduce neuroinflammation without any observable negative impact on organoid function. Further testing of these top Nanoligomer combinations in an aggressive experimental autoimmune encephalomyelitis (EAE) mouse model for MS using intraperitoneal (IP) injections showed that NF-κB1 and NLRP3 targeting Nanoligomer combination NI112 rescues mice without observable loss of mobility or disability, minimal inflammation in brain and spinal cord histology, and minimal to no immune cell infiltration of the spinal cord and no demyelination, similar to or at par with mice that received no EAE injections (negative control). Mice receiving NI111 (NF-κB1 + TNFR1) also showed reduced neuroinflammation compared to saline (sham)-treated EAE mice and at par/similar to other inflammasome-inhibiting small molecule treatments, although it was significantly higher than NI112 leading to subsequent worsening clinical outcomes. Furthermore, treatment with an oral formulation of NI112 at lower doses showed a significant reduction in EAE severity, albeit with higher variance owing to administration and formulation/fill-and-finish variability. Overall, these results point to the potential of further development and testing of these inflammasome-targeting Nanoliogmers as an effective neuroinflammation treatment for multiple neurodegenerative diseases and potentially benefit several patients suffering from such debilitating autoimmune diseases like MS.

Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions

Linomide Suppresses Both Th1 and Th2 Cytokines in Experimental Autoimmune Myasthenia Gravis

Linomide-mediated Protection of Oligodendrocytes is Associated with Inhibition of Nitric Oxide Production and IL-1β Expression in Lewis Rat Glial Cells

Lactobacillus Rhamnosus Ameliorates Experimental Autoimmune Neuritis Via Modulation of Gut Microbiota and Metabolites.

A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects Against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice.

Selective elimination of macrophages by dichlormethylene diphosphonate-containing liposomes suppresses experimental autoimmune neuritis

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model

Effects on Experimental Allergic Neuritis in Rats by in Vivo Treatment with Monoclonal Anti-T-cell Antibodies

Effects of Huanglian Wendan Decoction on Experimental Autoimmune Neuritis in Lewis Rats

SIN-1, a Nitric Oxide Donor, Ameliorates Experimental Allergic Encephalomyelitis in Lewis Rats in the Incipient Phase: the Importance of the Time Window

Targeted-Neuroinflammation Mitigation Using Inflammasome-Inhibiting Nanoligomers is Therapeutic in an Experimental Autoimmune Encephalomyelitis Mouse Model

Combined Nasal Administration of Encephalitogenic Myelin Basic Protein Peptide 68–86 and IL-10 Suppressed Incipient Experimental Allergic Encephalomyelitis in Lewis Rats

Modulation of experimental autoimmune neuritis in Lewis rats by oral application of myelin antigens

The Complexity of Cytokine Treatment in Ongoing EAE Induced with MBP Peptide 68–86 in Lewis Rats

Induction of Regulatory Properties in the Intestinal Immune System by Dimethyl Fumarate in Lewis Rat Experimental Autoimmune Neuritis

Nervonic acid regulates the oxidative imbalance in experimental allergic encephalomyelitis

Modulation of the HMGB1/TLR4/NF-κB signaling pathway in the CNS by matrine in experimental autoimmune encephalomyelitis

Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats

Linomide, a New Immunomodulatory Drug, Shows Different Effects on Homologous Versus Heterologous Collagen-Induced Arthritis in Rats.

[Linarin inhibits microglia activation-mediated neuroinflammation and neuronal apoptosis in mouse spinal cord injury by inhibiting the TLR4/NF-κB pathway]